9.30 am  – 4.30 pm (EST) | 6.30 am – 1.30 pm (PST)

* Please note that the following agenda timings are Eastern Time.
For Pacific Times, please download the full event guide here

9:30 am | Coffee Networking Session

9:50 am Chair’s Opening Remarks

Clinical Trial Case Studies

10:00 am Correlative Analysis to Assess Modulation to the Tumor Microenvironment

  • Aiman Shalabi VP, Medicines Development Leader, Cell and Gene Therapies, GSK

Synopsis

  • Review biopsy material pre and post treatment to analyse the changes in the tumor microenvironment caused by the cell therapy
  • Outline trafficking activity of the cells to the tumor site and understand if they are functioning when in the TME
  • Assessing efficacy and safety data

Solid Tumor Clinical Development Strategies

10:30 am Current Status of Clinical Trial Strategies for Solid Tumors

  • Tanja Obradovic Senior Scientific Director, Cell Therapy/ Redirected Immunity, Takeda

Synopsis

  • Review the cell therapy clinical trials distribution in various solid tumors and by clinical trial phases
  • Understand how cell therapy treatments align with current lines of therapy in solid tumours
  • Review patient population characteristics and exclusion criteria
  • Dosing schedules and tactics to optimize cell therapy delivery

11:00 am

Speed Networking and Refreshment Break

Synopsis

Like speed dating, but for business! Turn on your camera and randomly connect with speakers, delegates and partners of the conference so you can meet as many people as possible. Your random connection could lead to your next collaboration!

Roundtable Discussion Session

12:30 pm  Join your colleagues for a collaborative and dynamic discussion session on the following…

Preparative Regimen to Not Only Create Space for the Cell Therapy, but to Address the Tumor Microenvironment

  • Preconditioning strategies to alter the immunosuppressive environment of the host to help the infused cells function well in the solid tumor environment
  • Strategies to curb the hostile microenvironment prior to infusion
  • Preconditioning combination approaches with chemotherapy, antibodies and cytokines, to prepare the tumor site to create a more hospitable environment, greater cell expansion and efficacy

Delivery Route of Administration to Improve Trafficking and Tumor Penetration

1:00 pm Phase I Evaluation of T4 CAR T-Cell Immunotherapy of Locally Advanced/Recurrent Head and Neck Cancer

  • John Maher CSO, Leucid Bio, & Senior Lecturer in Immunology Kings College London

Synopsis

  •  T4 immunotherapy consists of autologous T-cells that co- express a Pan-ErbB targeted CAR (T1E28z) and an IL-4 responsive chimeric cytokine receptor, 4ab
  • Cell products are manufactured from a blood draw in a 2 week closed GMP process, using IL-4 to drive expansion of transduced cells
  • Sixteen patients have received intra-tumoural T4 CAR T-cells at doses of up to 1 billion cells, without any dose-limiting toxicities and attainment of stable disease in 10 cases

1:30 pm | Lunch Refreshments and Networking

Combination Approaches to Conquer Solid Tumors

2:30 pm A Phase I/IIa Trial to Evaluate Safety and Efficacy of CLDN6 CAR-T and CARVac Based In Vivo Expansion to Improve Treatment of Patients with CLDN6-Positive Advanced Solid Tumors

Synopsis

  • Preliminary Ph1 data on FIH trial with CLDN6-CART +/- CARVac incl. safety, PK/PD and efficacy data
  • Focus on combination with CARVac for in vivo expansion of CLDN6-CART
  • Update on exploratory biomarker program

3:00 pm SIRPa-Deficient Macrophage Combination Against Solid Tumor

  • Yuan Liu Professor, Immunology & Cell Biology, Georgia State University

Synopsis

  • Intratumoral SIRPa-deficient macrophage combined with local radiotherapy eliminate late-stage colorectal and pancreatic cancers
  • Induce robust activation of tumor-specific T cells for cytotoxicity
  • Reprogram TME into a proinflammatory cancer-killing niche

3:30 pm Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration

Synopsis

  • Proposed mode of action
  • Preclinical in vivo data in combination with anti-VEGF antibodies and checkpoint inhibitors
  • Clinical data from a randomized phase 2 study in mRCC in combination with sunitinib (VEGFR-TKI) leading to Regenerative Medicine Advanced Therapy Designation by FDA

Early Manufacturing Considerations for Solid Tumors

4:00 pm iPSC-Derived NK cell (iNK) Iterations and NK Engagers to Target and Kill Solid Tumors

Synopsis

• Potential of iNK as therapeutics
• Potential role and synergy of NKp46 engagement

4:30 pm Solid Tumor Targeting with GEN-011: An Autologous Multi- Neoantigens-Specific Peripheral-Blood Derived T Cell Therapy

  • Pranay Khare Director, Cell Therapy Development & Manufacturing, Genocea

Synopsis

• Importance of tumor-specific neoantigen selection with ATLASTM bioassay for cancer immunotherapies
• Discuss the plan for a robust, scalable, reproducible and closed “PLANET” manufacturing process
• GEN-011 is an autologous, multi-neoantigen-specific T cell therapy with memory T cells phenotype and harboring self-renewing, stem-like characteristics

4:30 pm Chair’s Closing Remarks